Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

APEC1621SC: Pediatric MATCH (Molecular Analysis for Therapy Choice)

APEC1621SC

Condition: Solid Tumor
Phase: N/A
Clinicaltrials.gov ID: NCT03155620

What is the goal of the study?

The goal of this phase 2 study is to evaluate patients' overall response rate to treatment.

Who can participate in the study?

This study may be a good fit for children and young adults who: - are between the ages of 12 months to 21 years old, and - have a diagnosis of recurrent or refractory solid tumors, including non-Hodgkin lymphomas; histiocytoses (e.g. langerhans cell histiocytosis [LCH], juvenile xanthogranuloma [JXG], histiocytic sarcoma); or central nervous system (CNS) tumors.

Study Team:

PI (Study Doctor): Katherine Tarlock
Study Team Member: HemOnc CRAs, HemOncCRAs@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.